1.36
Precedente Chiudi:
$1.33
Aprire:
$1.34
Volume 24 ore:
68,516
Relative Volume:
0.28
Capitalizzazione di mercato:
$138.50M
Reddito:
$17.85M
Utile/perdita netta:
$-96.93M
Rapporto P/E:
-0.5498
EPS:
-2.4735
Flusso di cassa netto:
$-88.29M
1 W Prestazione:
-6.21%
1M Prestazione:
-9.93%
6M Prestazione:
-61.80%
1 anno Prestazione:
-72.80%
Nyxoah Sa Stock (NYXH) Company Profile
Nome
Nyxoah Sa
Settore
Industria
Telefono
-
Indirizzo
-
Compare NYXH vs ISRG, BDX, RMD, MDLN, ALC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
NYXH
Nyxoah Sa
|
1.36 | 147.67M | 17.85M | -96.93M | -88.29M | -2.4735 |
|
ISRG
Intuitive Surgical Inc
|
391.95 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
176.80 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
RMD
Resmed Inc
|
218.89 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
35.61 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
ALC
Alcon Inc
|
63.76 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-31 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2022-04-21 | Iniziato | Oppenheimer | Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Peer Perform |
| 2021-12-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Nyxoah Sa Borsa (NYXH) Ultime notizie
Nyxoah (NASDAQ: NYXH) Stock Price, News & Analysis - Kalkine
With Genio approved by the FDA and launched in the U.S., Nyxoah (NYXH) names a new CEO - Stock Titan
Nyxoah Appoints New CEO to Drive US Expansion - Sleep Review
Discontinued operations of Nyxoah SA – HAN:5YI - TradingView
Nyxoah names Liam Kelly as CEO - Medical Buyer
Nyxoah SA Announces CEO Changes, Effective October 1, 2026 - marketscreener.com
A former medical-device CEO will lead Nyxoah while its U.S. launch is still in early stages. - Stock Titan
Nyxoah Appoints Liam Kelly as Chief Executive Officer - GlobeNewswire
Nyxoah Names Former CFO Loïc Moreau as Interim Finance Chief, Reaffirms 2026 Guidance - The Globe and Mail
CFO John Landry to leave Nyxoah (NASDAQ: NYXH) in 2026 as company searches for his successor - Stock Titan
NYXH.BB Price History for Nyxoah Sa Stock - Barchart.com
Nyxoah shares fall after CFO departure announcement - Investing.com
Nyxoah shares fall after CFO departure announcement By Investing.com - Investing.com Australia
Nyxoah announces CFO transition, reaffirms 2026 guidance By Investing.com - Investing.com India
Nyxoah announces CFO transition, reaffirms 2026 guidance - Investing.com
A medical technology company expects €36M–€40M in 2026 revenue. Nyxoah’s finance chief is set to leave. - Stock Titan
Nyxoah Announces Chief Financial Officer Transition - Finansavisen
Nyxoah SA(ENXTBR: NYXH) dropped from S&P Global BMI Index - marketscreener.com
Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6 By Investing.com - Investing.com South Africa
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption? - Yahoo Finance
Nyxoah SA Actuals & Estimates (HAM:5YI) - TradingView
Gross profit of Nyxoah SA – HAM:5YI - TradingView
Price to book ratio of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Begins U.S. Post-Approval Study of Genio Sleep Apnea Implant - finance.biggo.com
Cash per share of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial - Yahoo Finance
Nyxoah implants first patient in BREATHE study of Genio - Yahoo
symbol__ Stock Quote Price and Forecast - CNN
Nyxoah Launches Major U.S. Post-Approval Study for Genio Sleep Apnea Device - TipRanks
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System - GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Nyxoah SA (NYXH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success - Investing.com
Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) - Seeking Alpha
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com India
NYXH Jumps As ACCCESS Trial Data Reset The Trading Map - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet - StocksToTrade
NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De-Risks U.S. Growth Story - StocksToTrade
Nyxoah stock surges as sleep apnea study hits endpoints - Investing.com
87.7% improved on a measure of oxygen drops during sleep. No device-related serious adverse events were reported. - Stock Titan
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary - GlobeNewswire
Nyxoah SA (NYXH) Stock Price & News - Syfe
Information on the total number of voting rights and shares - Finansavisen
Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateEarnings Power Value - vinanet.vn
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseIndex Put Call - vinanet.vn
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com Nigeria
Cantor Fitzgerald cuts Nyxoah stock price target on valuation - Investing.com
Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price - MarketBeat
NYXH Q2 2026 Earnings: EPS Miss of 46.48% Overshadowed by 2.53% Share GainCapex Guidance - vinanet.vn
Nyxoah Sa Azioni (NYXH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):